StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Soliris (eculizumab) — Europe YoY CER by Quarter

Soliris (eculizumab) — Europe YoY CER (%) (%)

QuarterlyAnnual

AstraZeneca Soliris (eculizumab) — Europe YoY CER: -50.0% in Q2 2026, up 4.0 pts from a year earlier.

Latest, Q2 2026
-50.0%
Period ended Jun 30, 2026
Change on a year earlier
+4.0 pts
-54.0% in Q2 2025
History
20 quarters
Since Q3 2021
Sources
20
Documents cited below

Where the Q2 2026 figure comes from

“|| Soliris | 389 | | ( 27 ) | | ( 28 ) | | 199 | | ( 29 ) | | 135 | | ( 15 ) | | ( 19 ) | | 28 | | ( 50 ) | | ( 50 ) | | 27 | | ( 21 ) | | ( 22 )”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Product Sales Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedSoliris (eculizumab) — Europe YoY CER (%) (%)Year on yearSource
Q2 2026Jun 30, 2026-50.0%+4.0 ptsForm 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 2026-49.0%+10.0 ptsForm 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 2025-46.0%+4.0 ptsForm 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 2025-49.0%-2.0 ptsForm 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 2025-54.0%-18.0 ptsForm 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 2025-59.0%-35.0 ptsForm 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 2024-50.0%-22.0 ptsForm 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 2024-47.0%-28.0 ptsForm 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 2024-36.0%-21.0 ptsForm 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 2024-24.0%-12.0 ptsForm 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 2023-28.0%-13.0 ptsForm 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 2023-19.0%-4.0 ptsForm 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 2023-15.0%-7.0 ptsForm 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 2023-12.0%-4.0 ptsForm 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 2022-15.0%-5.0 ptsForm 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 2022-15.0%-12.0 ptsForm 6-K FY2022Q3 Earnings Release ↗

Cite this data

StockData. (2026). AstraZeneca Soliris (eculizumab) — Europe YoY CER (%), quarterly Q3 2021–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-soliris-eu-cer-yoy

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.